Search

Your search keyword '"van Dijk, Anneke D."' showing total 7 results
Start Over Author "van Dijk, Anneke D." Journal blood
7 results on '"van Dijk, Anneke D."'

4. Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Author

van Dijk, Anneke D., primary, Ruvolo, Peter P., additional, Hoff, Fieke W, additional, Qiu, Yihua, additional, Gamis, Alan S, additional, Aplenc, Richard, additional, Kolb, Anders E., additional, Alonzo, Todd A., additional, Gerbing, Robert B., additional, de Bont, Eveline S., additional, Bruggeman, Sophia W.M., additional, Horton, Terzah M, additional, and Kornblau, Steven M., additional

Published
2019
Full Text
View/download PDF

5. Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

Author

van Dijk, Anneke D., primary, Hoff, Fieke W, additional, Qiu, Yihua, additional, Figueroa, Mary, additional, Chandra, Joya, additional, Jabbour, Elias, additional, de Bont, Eveline S., additional, and Kornblau, Steven M., additional

Published
2019
Full Text
View/download PDF

7. Prognostic Significance of FOXO3in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Author

van Dijk, Anneke D., Ruvolo, Peter P., Hoff, Fieke W, Qiu, Yihua, Gamis, Alan S, Aplenc, Richard, Kolb, Anders E., Alonzo, Todd A., Gerbing, Robert B., de Bont, Eveline S., Bruggeman, Sophia W.M., Horton, Terzah M, and Kornblau, Steven M.

Abstract

The proteasome degrades unneeded and damaged proteins. Tumor cells highly depend on increased protein production and their degradation suggesting that malignant cells with a high proliferation index will be more sensitive to proteasome inhibition. The addition of the proteasome inhibitor Bortezomib (Velcade, 'BTZ') to standard pediatric AML chemotherapy (cytarabine, daunorubicin and etoposide, 'ADE') depleted leukemia-initiating cells in a phase 2 clinical trial in pediatric AML (pedi-AML) patients. A randomized phase 3 clinical trial was then conducted by the Children's Oncology Group (COG) comparing ADE and ADE+BTZ treatment regimes in pedi-AML (AAML1031). To determine if there were specific protein expression profiles that correlated with response to BTZ-containing chemotherapy, we analyzed key components of the proteome of pedi-AML that participated in the trial using reverse phase protein arrays (RPPA).

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results